Key Takeaways
- • The European Investment Bank (EIB) and European Commission are deploying €35 million (US$39.8 million) in venture debt financing to Colombian biotech firm VaxThera, with a €15 million (US$17 million) first tranche announced at the UN General Assembly on September 26, 2026.
- • VaxThera will use capital to construct and validate a second phase of its integrated vaccine manufacturing facility, enabling production of up to 250 million doses annually in normal operations, with pandemic surge capacity of 600–700 million doses.
- • The financing structure utilizes venture debt—a non-dilutive funding mechanism that does not require equity surrender—and is backed by the EU's Global Gateway sustainable infrastructure investment strategy.
- • The investment strengthens vaccine manufacturing localization in Latin America, reducing regional dependency on external supply chains and supporting pandemic preparedness across the continent.
- • Capital will fund the entire vaccine manufacturing cycle, including upstream processing and precision filling for both liquid and lyophilized biological products.
Summary
The European Investment Bank and European Commission have approved a €35 million venture debt facility for VaxThera, a Colombian biotechnology company specializing in vaccine development and biopharmaceutical manufacturing. The first €15 million tranche was announced during the 81st United Nations General Assembly in New York, marking a strategic European capital injection into Latin American vaccine production capacity. The financing package represents the EIB's commitment to strengthening pharmaceutical manufacturing infrastructure in emerging markets and aligns with the European Union's Global Gateway framework for sustainable infrastructure investment worldwide.
VaxThera will deploy the capital for construction, fitting-out, and validation of the second phase of its large-scale integrated production facility. Upon completion, the expanded plant will achieve annual manufacturing capacity of 250 million doses of liquid and lyophilized biological products under normal operations. In pandemic scenarios, the facility can surge production to between 600 and 700 million doses annually, substantially enhancing regional biosecurity and vaccine accessibility across Latin America.
The venture debt structure is strategically significant for the beneficiary company. Unlike traditional bank lending, venture debt does not require extensive historical profitability or substantial physical collateral. Instead, it is extended to companies already backed by venture capital funds, preserving equity ownership while providing growth capital. This mechanism allows VaxThera to expand manufacturing capacity without diluting shareholder interests—a critical consideration for biotech firms scaling production infrastructure.
The manufacturing facility will encompass the complete vaccine production cycle, including upstream processing and precision filling capabilities. This comprehensive integration positions VaxThera to develop, manufacture, and commercialize vaccines independently, reducing supply chain vulnerabilities in the region and supporting the continent's pandemic preparedness infrastructure. The investment advances the broader EU objective of decentralizing pharmaceutical manufacturing and building manufacturing self-sufficiency in strategic geographies.
VaxThera will deploy the capital for construction, fitting-out, and validation of the second phase of its large-scale integrated production facility. Upon completion, the expanded plant will achieve annual manufacturing capacity of 250 million doses of liquid and lyophilized biological products under normal operations. In pandemic scenarios, the facility can surge production to between 600 and 700 million doses annually, substantially enhancing regional biosecurity and vaccine accessibility across Latin America.
The venture debt structure is strategically significant for the beneficiary company. Unlike traditional bank lending, venture debt does not require extensive historical profitability or substantial physical collateral. Instead, it is extended to companies already backed by venture capital funds, preserving equity ownership while providing growth capital. This mechanism allows VaxThera to expand manufacturing capacity without diluting shareholder interests—a critical consideration for biotech firms scaling production infrastructure.
The manufacturing facility will encompass the complete vaccine production cycle, including upstream processing and precision filling capabilities. This comprehensive integration positions VaxThera to develop, manufacture, and commercialize vaccines independently, reducing supply chain vulnerabilities in the region and supporting the continent's pandemic preparedness infrastructure. The investment advances the broader EU objective of decentralizing pharmaceutical manufacturing and building manufacturing self-sufficiency in strategic geographies.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.